# presbyopia in adults FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/presbyopia-in-adults

> No upcoming FDA catalysts in presbyopia in adults; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 31, 2025 | [LNZ100 FDA approval](https://sec-api.dev/pdufa/lnz100) | LENZ | presbyopia in adults | completed, approved | "•Announced FDA approval of VIZZ for the treatment of presbyopia on July 31, 2025 as the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/a991q325pressrelease.htm)) |
| October 16, 2026 | [Opus Genetics, Inc. label expansion decision](https://sec-api.dev/companies/ird/catalysts) | IRD | presbyopia in adults | completed, approved | "On October 16, 2026, the FDA approved the Company's supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia in adults." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1228627/000162828026072697/ird-20260930.htm)) |
| November 5, 2026 | [RYZUMVI (ryzumvi) FDA approval](https://sec-api.dev/pdufa/ryzumvi) | VTRS | presbyopia in adults | completed, approved | "•In October, the Company announced that the FDA approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/exhibit991-3q26earningsrel.htm)) |

## Drugs

- [LNZ100](https://sec-api.dev/pdufa/lnz100) (LENZ)
- [RYZUMVI (ryzumvi)](https://sec-api.dev/pdufa/ryzumvi) (IRD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/presbyopia-in-adults.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "presbyopia in adults FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/presbyopia-in-adults

```bibtex
@misc{secapidev_indications_presbyopia_in_adults_20261116,
  title        = {presbyopia in adults FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/presbyopia-in-adults}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_presbyopia_in_adults_20261116","title":"presbyopia in adults FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/presbyopia-in-adults","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
